-
Je něco špatně v tomto záznamu ?
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
H. Ludwig, M. Delforge, T. Facon, H. Einsele, F. Gay, P. Moreau, H. Avet-Loiseau, M. Boccadoro, R. Hajek, M. Mohty, M. Cavo, MA. Dimopoulos, JF. San-Miguel, E. Terpos, S. Zweegman, L. Garderet, MV. Mateos, G. Cook, X. Leleu, H. Goldschmidt, G....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu konsensus - konference, časopisecké články, přehledy
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- cílená molekulární terapie škodlivé účinky MeSH
- hodnocení rizik MeSH
- incidence MeSH
- lidé MeSH
- management nemoci MeSH
- mnohočetný myelom komplikace farmakoterapie MeSH
- nežádoucí účinky léčiv diagnóza epidemiologie prevence a kontrola terapie MeSH
- protinádorové látky škodlivé účinky terapeutické užití MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- přehledy MeSH
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.
A 'Seràgnoli' Institute of Hematology Bologna University School of Medicine Bologna Italy
Department of Hematology Amyloidosis and Myeloma Unit Hospital Clínic de Barcelona Spain
Department of Hematology and Oncology University of Freiburg Medical Center Freiburg Germany
Department of Hematology and Oncology University of Tuebingen Tuebingen Germany
Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands
Department of Hematology Lille University Hospital Lille France
Department of Hematology Newcastle University Newcastle UK
Department of Hematology Sahlgrenska Hospital Gothenburg Sweden
Department of Hematology St Olavs Hospital and IKOM NTNU Trondheim Norway
Department of Hematology University Hospital Leuven Catholic University Leuven Leuven Belgium
Department of Hematology University Hospital of Liège Liège Belgium
Department of Hematology University Hospital University of Nantes Nantes France
Department of Hematology VU University Medical Center Amsterdam The Netherlands
Department of Internal Medicine 2 University Hospital of Wuerzburg Wuerzburg Germany
Department of Medicine Ankara University Ankara Turkey
Department of Oncology and Hematology Cantonal Hospital St Gallen St Gallen Switzerland
Division of Hematology Citta della Salute e della Scienza University of Torino Torino Italy
Faculty of Medicine University Hospital Ostrava University of Ostrava Ostrava Czech Republic
Hospital Universitario de Salamanca Instituto Biosanitario de Salamanca Salamanca Spain
Leeds Institute of Cancer and Pathology University of Leeds Leeds UK
Myeloma Group The Institute of Cancer Research ICR London UK
National Center for Tumor Diseases Heidelberg Medical University Heidelberg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028450
- 003
- CZ-PrNML
- 005
- 20240528153652.0
- 007
- ta
- 008
- 190813s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-018-0040-1 $2 doi
- 035 __
- $a (PubMed)29720735
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ludwig, Heinz $u Wilhelminen Cancer Research Institute, Vienna, Austria. heinz.ludwig@wienkav.at.
- 245 10
- $a Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network / $c H. Ludwig, M. Delforge, T. Facon, H. Einsele, F. Gay, P. Moreau, H. Avet-Loiseau, M. Boccadoro, R. Hajek, M. Mohty, M. Cavo, MA. Dimopoulos, JF. San-Miguel, E. Terpos, S. Zweegman, L. Garderet, MV. Mateos, G. Cook, X. Leleu, H. Goldschmidt, G. Jackson, M. Kaiser, K. Weisel, NWCJ. van de Donk, A. Waage, M. Beksac, UH. Mellqvist, M. Engelhardt, J. Caers, C. Driessen, J. Bladé, P. Sonneveld,
- 520 9_
- $a During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a nežádoucí účinky léčiv $x diagnóza $x epidemiologie $x prevence a kontrola $x terapie $7 D064420
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a cílená molekulární terapie $x škodlivé účinky $7 D058990
- 650 _2
- $a mnohočetný myelom $x komplikace $x farmakoterapie $7 D009101
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a hodnocení rizik $7 D018570
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Delforge, Michel $u Department of Hematology, University Hospital Leuven, Catholic University Leuven, Leuven, Belgium.
- 700 1_
- $a Facon, Thierry $u Department of Hematology, Lille University Hospital, Lille, France.
- 700 1_
- $a Einsele, Hermann $u Department of Internal Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany.
- 700 1_
- $a Gay, Francesca $u Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
- 700 1_
- $a Moreau, Philippe $u Department of Hematology, University Hospital, University of Nantes, Nantes, France.
- 700 1_
- $a Avet-Loiseau, Hervé $u Centre de Recherches en Cancerologie de Toulouse CRCT, Institut National de la Sante et de la Recherche Medicale, Université Toulouse, Toulouse, France.
- 700 1_
- $a Boccadoro, Mario $u Division of Hematology, Citta della Salute e della Scienza, University of Torino, Torino, Italy.
- 700 1_
- $a Hajek, Roman $u Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Mohty, Mohamad $u Department of Haematology, Saint Antoine Hospital, University Pierre and Marie Curie, and INSERM UMRs 938, Paris, France. $7 xx0317729
- 700 1_
- $a Cavo, Michele $u A 'Seràgnoli' Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
- 700 1_
- $a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- 700 1_
- $a San-Miguel, Jesús F $u Department of Hematology, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
- 700 1_
- $a Terpos, Evangelos $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- 700 1_
- $a Zweegman, Sonja $u Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Garderet, Laurent $u Department of Haematology, Saint Antoine Hospital, University Pierre and Marie Curie, and INSERM UMRs 938, Paris, France.
- 700 1_
- $a Mateos, María-Victoria $u Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.
- 700 1_
- $a Cook, Gordon $u Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
- 700 1_
- $a Leleu, Xavier $u Service d'Hématologie et Thérapie Cellulaire, PRC, and Inserm CIC1402, Hospital de la Miléterie, Poitiers, France.
- 700 1_
- $a Goldschmidt, Hartmut $u National Center for Tumor Diseases, Heidelberg Medical University, Heidelberg, Germany.
- 700 1_
- $a Jackson, Graham $u Department of Hematology, Newcastle University, Newcastle, UK.
- 700 1_
- $a Kaiser, Martin $u Myeloma Group, The Institute of Cancer Research ICR, London, UK.
- 700 1_
- $a Weisel, Katja $u Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
- 700 1_
- $a van de Donk, Niels W C J $u Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Waage, Anders $u Department of Hematology, St. Olavs Hospital, and IKOM, NTNU, Trondheim, Norway.
- 700 1_
- $a Beksac, Meral $u Department of Medicine, Ankara University, Ankara, Turkey.
- 700 1_
- $a Mellqvist, Ulf H $u Department of Hematology, Sahlgrenska Hospital, Gothenburg, Sweden.
- 700 1_
- $a Engelhardt, Monika $u Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.
- 700 1_
- $a Caers, Jo $u Department of Hematology, University Hospital of Liège, Liège, Belgium.
- 700 1_
- $a Driessen, Christoph $u Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- 700 1_
- $a Bladé, Joan $u Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic de Barcelona, Spain.
- 700 1_
- $a Sonneveld, Pieter $u Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 32, č. 7 (2018), s. 1542-1560
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29720735 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20240528153649 $b ABA008
- 999 __
- $a ok $b bmc $g 1433599 $s 1066910
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 32 $c 7 $d 1542-1560 $e 20180502 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20190813
